Scholar Rock is a pre-revenue biotech with a cash-heavy balance sheet ($437.1M in 2026Q2) funding an accelerating burn (quarterly FCF worsened from -$49.8M in 2024Q1 to -$69.6M in 2026Q2) as it advances apitegromab toward the pivotal SAPPHIRE readout.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue remains absent across all ten quarters, with net losses widening from -$56.9M in 2024Q1 to -$109.9M in 2026Q2, reflecting a 93% increase in quarterly burn and no gross margin.
The bull case envisions apitegromab becoming a multi-billion-dollar drug through label expansions into other neuromuscular conditions.
The oncology program with SRK-181 could yield a second commercial product, diversifying Scholar Rock's revenue streams.
Positive regulatory momentum with the FDA and a clear execution path for a 2026 US launch of apitegromab are key bullish drivers.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.84+0.1% vs -$0.84 | — vs $70,000 |
Q2 2026 May 7, 2026 | -$0.83-1.2% vs -$0.82 | — vs $5M |
Q2 2026 Mar 3, 2026 | -$0.88+0.3% vs -$0.88 | — vs $2M |
Q4 2025 Nov 14, 2025 | -$0.90-7.8% vs -$0.84 | — vs $50,000 |
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 17,461 shares of common stock and inducement restricted stock units, covering an aggregate of 43,559 shares of its common stock. The awards are subject to all terms and conditions and other provisi.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA). Informed by ongoing dialogue.
Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 1,414,143 shares. The stock had previously closed at $46.81.
Benchmark SRRK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Scholar Rock Holding Corporation (SRRK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $46.94 | $5.62B | -15.01 | — | — | -160.19% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $25.55 | $3.2B | 116.88 | 91.34% | 5.88% | 14.18% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $399.63 | $9.21B | -77.92 | 432.05% | -10.89% | -27.07% | — | |
| $7.97 | $417.26M | -17.11 | -92.84% | -45.43% | -8.34% | — |
Scholar Rock Holding Corporation (SRRK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Scholar Rock Holding Corporation (SRRK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Jun 5, 2026·SEC
Get notified when SRRK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Scholar Rock Holding Corporation (SRRK) stock FAQ — growth, dividends, profitability & financials explained
No. Scholar Rock Holding Corporation (SRRK) reported a net loss of $408.6M over the trailing twelve months.
Scholar Rock Holding Corporation (SRRK) had a return on equity (ROE) of -160.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Scholar Rock Holding Corporation (SRRK) had negative free cash flow of $296.3M over the trailing twelve months.
